Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial.

J Headache Pain · 2021 · PMC8052719 · PMID 33863272

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

did not reach statistical significanceP = 0.055so close (0.05 < p ≤ 0.1)

Differences between the fremanezumab and placebo groups did not reach statistical significance in Finland (quarterly fremanezumab, OR [95% CI], 4.19 [0.97, 18.10]; P = 0.055; monthly fremanezumab, 3.25 [0.75, 14.12]; P = 0.116).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.